.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
Colorcon
Baxter
McKinsey
Accenture
Medtronic
Harvard Business School
QuintilesIMS
Novartis
Merck

Generated: December 16, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021731

« Back to Dashboard

NDA 021731 describes ELIGARD, which is a drug marketed by Tolmar Therap and is included in four NDAs. It is available from one supplier. There are nine patents protecting this drug. Additional details are available on the ELIGARD profile page.

The generic ingredient in ELIGARD is leuprolide acetate. There are twenty-one drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the leuprolide acetate profile page.

Summary for 021731

Tradename:1
Applicant:1
Ingredient:1
Patents:8
Therapeutic Class:Hormonal Agents, Suppressant (Pituitary)
Formulation / Manufacturing:see details

Medical Subject Heading (MeSH) Categories for 021731

Suppliers and Packaging for NDA: 021731

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ELIGARD leuprolide acetate INJECTABLE;SUBCUTANEOUS 021731 NDA TOLMAR PHARMACEUTICALS INC. 62935-452 62935-452-45 1 KIT in 1 CARTON (62935-452-45) * .375 mL in 1 SYRINGE (62935-450-45) * .375 mL in 1 SYRINGE (62935-451-44)
ELIGARD leuprolide acetate INJECTABLE;SUBCUTANEOUS 021731 NDA TOLMAR PHARMACEUTICALS INC. 62935-453 62935-453-45 1 KIT in 1 CARTON (62935-453-45) * .375 mL in 1 SYRINGE (62935-454-44) * .375 mL in 1 SYRINGE (62935-455-45)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;SUBCUTANEOUSStrength45MG/VIAL
Approval Date:Dec 14, 2004TE:RLD:Yes
Patent:► SubscribePatent Expiration:Oct 28, 2018Product Flag?YSubstance Flag?Delist Request?
Patented Use:METHOD OF TREATING CANCER
Patent:► SubscribePatent Expiration:Mar 27, 2020Product Flag?YSubstance Flag?Delist Request?
Patent:► SubscribePatent Expiration:Oct 28, 2018Product Flag?Substance Flag?Delist Request?
Patented Use:METHOD OF TREATING CANCER

Expired Orange Book Patents for NDA: 021731

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Tolmar TherapELIGARDleuprolide acetateINJECTABLE;SUBCUTANEOUS021731-001Dec 14, 2004► Subscribe► Subscribe
Tolmar TherapELIGARDleuprolide acetateINJECTABLE;SUBCUTANEOUS021731-001Dec 14, 2004► Subscribe► Subscribe
Tolmar TherapELIGARDleuprolide acetateINJECTABLE;SUBCUTANEOUS021731-001Dec 14, 2004► Subscribe► Subscribe
Tolmar TherapELIGARDleuprolide acetateINJECTABLE;SUBCUTANEOUS021731-001Dec 14, 2004► Subscribe► Subscribe
Tolmar TherapELIGARDleuprolide acetateINJECTABLE;SUBCUTANEOUS021731-001Dec 14, 2004► Subscribe► Subscribe
Tolmar TherapELIGARDleuprolide acetateINJECTABLE;SUBCUTANEOUS021731-001Dec 14, 2004► Subscribe► Subscribe
Tolmar TherapELIGARDleuprolide acetateINJECTABLE;SUBCUTANEOUS021731-001Dec 14, 2004► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Farmers Insurance
US Department of Justice
McKinsey
McKesson
Medtronic
Cerilliant
Cantor Fitzgerald
Novartis
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot